Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
Timothy Devos(Rega Institute for Medical Research), Geert Meyfroidt(KU Leuven), Piet Maes(Rega Institute for Medical Research), Albrecht Betrains(KU Leuven), Cyril Barbezange(Sciensano (Belgium)), Martial Moonen(Centre Hospitalier Chrétien), Kevin K. Ariën(University of Antwerp), Michel Moutschen(University of Liège), Laurent Jadot(Centre Hospitalier Chrétien), Matthias M. Engelen(KU Leuven), Tomé Najdovski, Niels Van Regenmortel(Antwerp University Hospital), Peter Verhamme(KU Leuven), Quentin Van Thillo(KU Leuven), Nicolás Dauby(Université Libre de Bruxelles), Laurens Liesenborghs(Instituut voor Tropische Geneeskunde), Iwein Gyselinck(Universitair Ziekenhuis Leuven), Veerle Compernolle(Vlaams Instituut voor Biotechnologie), Ann Belmans(KU Leuven), Sarah Loof(AZ Maria Middelares), Lucie Seyler(Universitair Ziekenhuis Brussel), Alexander Schauwvlieghe(AZ Sint-Jan), Evelyne Maillart(Erasmus Hospital), Mutien‐Marie Garigliany(University of Liège), Mathias Leys(AZ Groeninge), Márta Romano(Institut Scientifique de Santé Publique)
Cited by 49
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
|New England Journal of Medicine|2019|945